Jobs
-
Vectura Group has confirmed that its US partner for the VR315 fluticasone/salmeterol DPI and the VR506 generic fluticasone propionate DPI is Boehringer Ingelheim subsidiary Roxane Laboratories. The company is partnered with Sandoz on VR315 in… Read more . . .
-
Swedish DPI developer Simplified Solutions announced that it has entered into an agreement with CSP Technologies for continued development of its X-haler dry powder inhaler through to commercial manufacturing. The credit-card sized multi-dose DPI will… Read more . . .
-
Qualcomm subsidiary Qualcomm Life will design a disposable module for the Breezhaler DPI that will sense and report inhaler usage data for Novartis’s Breezhaler COPD products, including Ultibro, Seebri, and Onbrez. The Breezhaler DPIs are… Read more . . .
-
Sanofi will return development and commercialization rights for Afrezza inhaled insulin to MannKind after disapponting sales, and MannKind says that it is considering strategic options for the product. Afrezza was approved by the FDA in… Read more . . .
-
Cipla has announced the launch of a mobile app called “My Breathefree,” which is intended to serve as a “virtual caregiver” for asthma patients in India. The app includes video demonstrations of correct use for… Read more . . .
-
Discovery Laboratories has announced the initiation of a Phase 2b trial of Aerosurf aerosolized KL4 surfactant to treat respiratory distress syndrome (RDS) in premature infants. The trial, which is expected to enroll up to 250… Read more . . .
-
Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma’s SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a… Read more . . .
-
GlaxoSmithKline has recalled two lots of Ventolin HFA metered dose inhalers totaling 128,704 inhalers, according to an FDA enforcement report. The company initiated the voluntary recall on December 3, 2015 due to concerns about insufficient… Read more . . .
-
Welcoming over 600 attendees to the Edinburgh International Conference Centre, conference chair Gary Pitcairn opened the meeting on December 9, 2015 by noting the 20% increase in attendance from DDL 25 and suggesting that next… Read more . . .
-
The FDA has granted orphan drug designation to Neurelis’s lead product, NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients, the company said. Biotie paid $1 million for an option to… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland